Industry

Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)

— Patients Aged 65+ Had Over Three-fold Improvement in Two-year Event-Free Survival (EFS) Rate, and Over Eight-fold Greater Median EFS and Clinically Meaningful Improvements in Quality of Life (QoL) with Yescarta vs SOC — — Separate Exploratory Analysis Found Yescarta Benefit vs SOC Was Consistent Across Subgroups, Including in Patients with High Tumor Burden and … [Read more…]

Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients

– At One Year, 3X as Many Patients Were Progression-Free Compared to Physicians’ Choice of Chemotherapy in Phase 3 TROPiCS-02 Study – – At The First Interim Analysis, Overall Survival Demonstrated a Positive Trend, Patients Will Continue to be Followed – – Analysis of Patient-Reported Outcomes Shows Trodelvy Also Improved Quality of Life over Physicians’ … [Read more…]

Circulating Tumor DNA Guides Chemotherapy Use in Stage II Colon Cancer

Researchers from TGen, a part of City of Hope, contribute to study supporting value of ctDNA in assessing treatment options PHOENIX–(BUSINESS WIRE)–Tumor DNA circulating in the bloodstream can help clinicians decide whether chemotherapy is right for their patients who have undergone surgery for stage II colon cancer, according to a breakthrough study published online in … [Read more…]

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® (palbociclib) in combination with letrozole compared to placebo plus letrozole for the first-line treatment of postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). With a median … [Read more…]

Sparrow Pharmaceuticals Presents New Pharmacological Data on HSD-1 Inhibitor SPI-62 at the 2022 Annual European Congress of Rheumatology

Results indicate that SPI-62 has the potential to mitigate adverse effects of glucocorticoid medications PORTLAND, Ore.–(BUSINESS WIRE)–Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, today presented new animal model data during an in-person poster session titled, “Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica” … [Read more…]

At Prides, AHF Invites All Communities to #StandAgainstHate

On the heels of divisive and dangerous ‘Don’t Say Gay’ bills targeting LGBTQ+ individuals and families in Florida, Ohio and other states and as LGBTQ+ Pride seasons kick off, AHF will take part in a dozen Prides and parades nationwide, with messaging that #We Stand United and must #StandAgainstHate Since 2021, 42 states have considered … [Read more…]

Biomarkers May Predict Better Immunotherapy Treatment Outcomes for Certain Patients with Pancreatic Cancer

Findings from the Parker Institute for Cancer Immunotherapy (PICI) and its collaborative network of researchers, including from the University of Pennsylvania, presented at 2022 ASCO Annual Meeting and published in Nature Medicine New data from the PRINCE clinical trial, co-funded by PICI, Bristol Myers Squibb and the Cancer Research Institute in collaboration with Apexigen, could … [Read more…]

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

Insulet Presents Pivotal Extension Data for Preschool Children and Other Omnipod® 5 System Clinical Research at American Diabetes Association 82nd Scientific Sessions ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new Omnipod® 5 Automated Insulin Delivery System … [Read more…]

Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech

Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval LOS ANGELES–(BUSINESS WIRE)–Oaktree Acquisition Corp. II (NYSE: OACB) (“OACB” or the “Company”) announced today that, assuming satisfaction of the conditions to the closing of its pending business combination with Alvotech Holdings S.A. and Alvotech (“Topco”) (the “Business Combination”), including approval of the … [Read more…]

Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the company has withdrawn a supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The Company could not appropriately address the U.S. Food and Drug Administration’s questions about the benefit-risk profile of Reblozyl … [Read more…]